H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 22.4 HKD 0.67%
Market Cap: 19.5B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

HUTCHMED (China) Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HUTCHMED (China) Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
HUTCHMED (China) Ltd
HKEX:13
Other Long-Term Assets
$37.3m
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
62%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Other Long-Term Assets
HK$892m
CAGR 3-Years
38%
CAGR 5-Years
51%
CAGR 10-Years
11%
U
United Laboratories International Holdings Ltd
HKEX:3933
Other Long-Term Assets
ÂĄ87.8m
CAGR 3-Years
-9%
CAGR 5-Years
-22%
CAGR 10-Years
-13%
Sino Biopharmaceutical Ltd
HKEX:1177
Other Long-Term Assets
ÂĄ989.3m
CAGR 3-Years
-39%
CAGR 5-Years
-12%
CAGR 10-Years
6%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Other Long-Term Assets
ÂĄ319.5m
CAGR 3-Years
19%
CAGR 5-Years
17%
CAGR 10-Years
-3%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Other Long-Term Assets
HK$6.1B
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
19.5B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.

Intrinsic Value
21.5 HKD
Overvaluation 4%
Intrinsic Value
Price
H

See Also

What is HUTCHMED (China) Ltd's Other Long-Term Assets?
Other Long-Term Assets
37.3m USD

Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Other Long-Term Assets amounts to 37.3m USD.

What is HUTCHMED (China) Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
62%

Over the last year, the Other Long-Term Assets growth was -6%. The average annual Other Long-Term Assets growth rates for HUTCHMED (China) Ltd have been 15% over the past three years , 21% over the past five years , and 62% over the past ten years .

Back to Top